Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Sarcoma | 23 | 2024 | 1897 | 2.990 |
Why?
|
Gastrointestinal Stromal Tumors | 9 | 2021 | 643 | 1.810 |
Why?
|
Liposarcoma | 9 | 2024 | 333 | 1.730 |
Why?
|
Soft Tissue Neoplasms | 12 | 2023 | 1363 | 1.630 |
Why?
|
Perivascular Epithelioid Cell Neoplasms | 3 | 2021 | 75 | 1.200 |
Why?
|
Antibiotics, Antineoplastic | 4 | 2021 | 692 | 1.110 |
Why?
|
Leiomyosarcoma | 5 | 2024 | 477 | 0.930 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 5 | 2019 | 380 | 0.910 |
Why?
|
Antineoplastic Agents | 18 | 2017 | 13695 | 0.780 |
Why?
|
Sirolimus | 3 | 2021 | 1564 | 0.700 |
Why?
|
Protein Kinase Inhibitors | 7 | 2021 | 5535 | 0.690 |
Why?
|
Albumins | 1 | 2021 | 569 | 0.660 |
Why?
|
Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2018 | 110 | 0.640 |
Why?
|
Gastrointestinal Neoplasms | 4 | 2019 | 990 | 0.620 |
Why?
|
Quinolines | 2 | 2013 | 732 | 0.610 |
Why?
|
Isoindoles | 1 | 2016 | 41 | 0.560 |
Why?
|
HSP90 Heat-Shock Proteins | 2 | 2016 | 434 | 0.540 |
Why?
|
Inservice Training | 1 | 2018 | 392 | 0.530 |
Why?
|
Karyopherins | 1 | 2016 | 137 | 0.520 |
Why?
|
Phenylurea Compounds | 3 | 2019 | 528 | 0.510 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2013 | 1660 | 0.510 |
Why?
|
Cytarabine | 1 | 2017 | 692 | 0.510 |
Why?
|
Hydrazines | 1 | 2016 | 226 | 0.490 |
Why?
|
Cyclin-Dependent Kinase 4 | 2 | 2015 | 538 | 0.480 |
Why?
|
Pyrroles | 6 | 2021 | 1146 | 0.450 |
Why?
|
Triazoles | 2 | 2016 | 911 | 0.440 |
Why?
|
Benzoquinones | 1 | 2013 | 201 | 0.440 |
Why?
|
Extremities | 1 | 2018 | 865 | 0.440 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 11 | 2023 | 11524 | 0.440 |
Why?
|
Electron Transport Complex II | 1 | 2012 | 48 | 0.440 |
Why?
|
Benzamides | 4 | 2016 | 1379 | 0.420 |
Why?
|
Pyrrolidinones | 1 | 2012 | 117 | 0.410 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2014 | 322 | 0.410 |
Why?
|
Xenograft Model Antitumor Assays | 4 | 2016 | 3557 | 0.410 |
Why?
|
Lactams, Macrocyclic | 1 | 2013 | 320 | 0.400 |
Why?
|
Granuloma, Plasma Cell | 1 | 2012 | 84 | 0.400 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2016 | 871 | 0.390 |
Why?
|
Proto-Oncogene Proteins c-met | 2 | 2012 | 578 | 0.380 |
Why?
|
Chondrosarcoma | 1 | 2013 | 309 | 0.380 |
Why?
|
Microphthalmia-Associated Transcription Factor | 1 | 2012 | 252 | 0.370 |
Why?
|
Nanoparticles | 1 | 2021 | 1905 | 0.360 |
Why?
|
Molecular Targeted Therapy | 3 | 2018 | 2727 | 0.360 |
Why?
|
Hedgehog Proteins | 1 | 2014 | 783 | 0.350 |
Why?
|
Genes, myc | 4 | 2000 | 399 | 0.350 |
Why?
|
Benzimidazoles | 1 | 2014 | 850 | 0.340 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2019 | 2942 | 0.340 |
Why?
|
Bone Neoplasms | 3 | 2022 | 2529 | 0.330 |
Why?
|
Indoles | 6 | 2017 | 1839 | 0.320 |
Why?
|
Oncogene Proteins, Fusion | 3 | 2018 | 1581 | 0.310 |
Why?
|
Sarcoma, Clear Cell | 3 | 2015 | 76 | 0.310 |
Why?
|
Tumor Suppressor Protein p53 | 7 | 2019 | 2948 | 0.310 |
Why?
|
Aminopyridines | 4 | 2021 | 542 | 0.310 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2022 | 9239 | 0.300 |
Why?
|
Imidazoles | 1 | 2013 | 1206 | 0.290 |
Why?
|
Spiro Compounds | 2 | 2017 | 76 | 0.280 |
Why?
|
Neoplasms | 8 | 2017 | 21683 | 0.280 |
Why?
|
Transplantation, Heterologous | 1 | 2014 | 2382 | 0.270 |
Why?
|
Proto-Oncogene Proteins c-myc | 5 | 1996 | 987 | 0.260 |
Why?
|
Dose-Response Relationship, Drug | 8 | 2019 | 10943 | 0.250 |
Why?
|
Health Personnel | 1 | 2018 | 3218 | 0.250 |
Why?
|
Electronic Health Records | 2 | 2018 | 4468 | 0.250 |
Why?
|
Mice, Nude | 4 | 2016 | 3689 | 0.250 |
Why?
|
Middle Aged | 42 | 2021 | 213383 | 0.240 |
Why?
|
Genomics | 2 | 2022 | 5720 | 0.240 |
Why?
|
TOR Serine-Threonine Kinases | 5 | 2016 | 2109 | 0.240 |
Why?
|
Neoplasm Metastasis | 6 | 2021 | 4851 | 0.240 |
Why?
|
Sarcoma, Alveolar Soft Part | 2 | 2015 | 41 | 0.240 |
Why?
|
Doxorubicin | 3 | 2021 | 2234 | 0.230 |
Why?
|
Administration, Oral | 5 | 2014 | 3913 | 0.230 |
Why?
|
Giant Cell Tumors | 2 | 2015 | 99 | 0.230 |
Why?
|
Connective Tissue | 2 | 2022 | 420 | 0.220 |
Why?
|
Maximum Tolerated Dose | 5 | 2019 | 892 | 0.220 |
Why?
|
Furans | 1 | 2024 | 194 | 0.220 |
Why?
|
Ketones | 1 | 2024 | 188 | 0.220 |
Why?
|
Deoxycytidine | 4 | 2019 | 826 | 0.220 |
Why?
|
Cell Cycle | 6 | 2014 | 2967 | 0.220 |
Why?
|
Humans | 70 | 2024 | 744343 | 0.210 |
Why?
|
Adult | 41 | 2022 | 214055 | 0.210 |
Why?
|
Drug Resistance, Neoplasm | 5 | 2019 | 5172 | 0.200 |
Why?
|
Male | 43 | 2023 | 350118 | 0.200 |
Why?
|
Hemangiosarcoma | 1 | 2024 | 239 | 0.200 |
Why?
|
Female | 45 | 2023 | 380194 | 0.200 |
Why?
|
Apoptosis | 9 | 2016 | 9727 | 0.190 |
Why?
|
Aged | 33 | 2021 | 163280 | 0.190 |
Why?
|
Piperazines | 6 | 2015 | 2488 | 0.190 |
Why?
|
Immunohistochemistry | 6 | 2014 | 11366 | 0.180 |
Why?
|
Piperidones | 1 | 2019 | 28 | 0.170 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2010 | 2915 | 0.170 |
Why?
|
Protein-Tyrosine Kinases | 3 | 2019 | 2455 | 0.170 |
Why?
|
Pathology, Clinical | 1 | 2023 | 368 | 0.170 |
Why?
|
Retroperitoneal Neoplasms | 1 | 2022 | 340 | 0.160 |
Why?
|
Acetates | 1 | 2019 | 311 | 0.160 |
Why?
|
Carbolines | 1 | 2019 | 265 | 0.160 |
Why?
|
Receptor, Macrophage Colony-Stimulating Factor | 2 | 2015 | 87 | 0.160 |
Why?
|
Treatment Outcome | 18 | 2024 | 63114 | 0.150 |
Why?
|
Neoplasm Proteins | 1 | 2010 | 3703 | 0.150 |
Why?
|
Genetic Predisposition to Disease | 1 | 2019 | 17446 | 0.150 |
Why?
|
Tunica Intima | 1 | 2019 | 464 | 0.150 |
Why?
|
Cell Line, Tumor | 6 | 2018 | 16689 | 0.150 |
Why?
|
Neoplasm Staging | 5 | 2021 | 11031 | 0.140 |
Why?
|
Sarcoma, Synovial | 1 | 2018 | 167 | 0.140 |
Why?
|
Endometrial Stromal Tumors | 1 | 2017 | 44 | 0.140 |
Why?
|
Pyrimidines | 5 | 2019 | 2942 | 0.140 |
Why?
|
Osteosarcoma | 1 | 2022 | 881 | 0.140 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2019 | 241 | 0.140 |
Why?
|
Proto-Oncogene Proteins c-kit | 3 | 2016 | 776 | 0.140 |
Why?
|
14-3-3 Proteins | 1 | 2017 | 214 | 0.140 |
Why?
|
Consensus | 2 | 2022 | 2959 | 0.140 |
Why?
|
Uterine Neoplasms | 2 | 2017 | 1513 | 0.140 |
Why?
|
Heart Neoplasms | 1 | 2019 | 374 | 0.140 |
Why?
|
DNA Mismatch Repair | 1 | 2019 | 426 | 0.130 |
Why?
|
Neoplasms, Second Primary | 1 | 2023 | 1061 | 0.130 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2019 | 640 | 0.130 |
Why?
|
Disease-Free Survival | 6 | 2017 | 6895 | 0.130 |
Why?
|
Transcription Factors | 4 | 2010 | 12208 | 0.130 |
Why?
|
Lung Neoplasms | 2 | 2018 | 13102 | 0.130 |
Why?
|
Efficiency | 1 | 2018 | 462 | 0.130 |
Why?
|
Dermatofibrosarcoma | 1 | 2015 | 63 | 0.120 |
Why?
|
Reactive Oxygen Species | 1 | 2022 | 2077 | 0.120 |
Why?
|
Self Efficacy | 1 | 2018 | 616 | 0.120 |
Why?
|
Phosphorylation | 3 | 2015 | 8436 | 0.120 |
Why?
|
Proto-Oncogene Proteins c-akt | 3 | 2013 | 2503 | 0.120 |
Why?
|
Benzofurans | 1 | 2014 | 140 | 0.120 |
Why?
|
Ornithine Decarboxylase | 1 | 1993 | 63 | 0.120 |
Why?
|
Retinoblastoma Protein | 2 | 2015 | 704 | 0.120 |
Why?
|
Injections, Intravenous | 1 | 2016 | 1420 | 0.120 |
Why?
|
Paraganglioma, Extra-Adrenal | 1 | 2013 | 46 | 0.120 |
Why?
|
Cyclins | 2 | 2001 | 603 | 0.120 |
Why?
|
Proto-Oncogene Proteins c-jun | 1 | 2014 | 286 | 0.120 |
Why?
|
Phosphoric Diester Hydrolases | 1 | 2014 | 197 | 0.110 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2016 | 730 | 0.110 |
Why?
|
Biopsy | 3 | 2023 | 6756 | 0.110 |
Why?
|
Mouth Diseases | 1 | 2015 | 241 | 0.110 |
Why?
|
Blotting, Western | 3 | 2016 | 5179 | 0.110 |
Why?
|
Biological Products | 1 | 2022 | 860 | 0.110 |
Why?
|
Gene Fusion | 2 | 2015 | 371 | 0.110 |
Why?
|
Succinate Dehydrogenase | 1 | 2013 | 146 | 0.110 |
Why?
|
Neoadjuvant Therapy | 2 | 2018 | 2728 | 0.110 |
Why?
|
Lymphatic Metastasis | 2 | 2018 | 2924 | 0.110 |
Why?
|
Salvage Therapy | 1 | 2019 | 1275 | 0.110 |
Why?
|
Prospective Studies | 6 | 2022 | 53288 | 0.110 |
Why?
|
Inhibitory Concentration 50 | 1 | 2013 | 459 | 0.110 |
Why?
|
Aged, 80 and over | 11 | 2021 | 57776 | 0.110 |
Why?
|
Phthalazines | 1 | 2014 | 363 | 0.100 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2015 | 664 | 0.100 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2018 | 3479 | 0.100 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2015 | 705 | 0.100 |
Why?
|
Hydroxamic Acids | 1 | 2014 | 494 | 0.100 |
Why?
|
Synovitis, Pigmented Villonodular | 1 | 2011 | 34 | 0.100 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 890 | 0.100 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2015 | 903 | 0.100 |
Why?
|
Tissue Array Analysis | 1 | 2013 | 553 | 0.100 |
Why?
|
Cell Differentiation | 6 | 2016 | 11483 | 0.100 |
Why?
|
Mutation | 9 | 2022 | 29786 | 0.100 |
Why?
|
Retrospective Studies | 11 | 2022 | 77449 | 0.090 |
Why?
|
Feedback, Physiological | 1 | 2013 | 479 | 0.090 |
Why?
|
Oncogene Proteins | 1 | 2014 | 749 | 0.090 |
Why?
|
Neoplasm Transplantation | 1 | 2014 | 2085 | 0.090 |
Why?
|
Young Adult | 15 | 2020 | 56430 | 0.090 |
Why?
|
Enzyme Activation | 2 | 2013 | 3701 | 0.090 |
Why?
|
Survival Rate | 3 | 2021 | 12788 | 0.090 |
Why?
|
GTP Phosphohydrolases | 1 | 2013 | 509 | 0.090 |
Why?
|
Aromatase Inhibitors | 1 | 2013 | 491 | 0.090 |
Why?
|
Gene Dosage | 1 | 2014 | 1252 | 0.090 |
Why?
|
Program Evaluation | 1 | 2018 | 2488 | 0.090 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2014 | 789 | 0.090 |
Why?
|
Trans-Activators | 2 | 2014 | 2924 | 0.090 |
Why?
|
Drug Administration Schedule | 5 | 2017 | 4933 | 0.080 |
Why?
|
PPAR gamma | 1 | 2012 | 493 | 0.080 |
Why?
|
Receptors, Progesterone | 1 | 2013 | 1097 | 0.080 |
Why?
|
Thiazolidinediones | 1 | 2012 | 476 | 0.080 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 1993 | 1213 | 0.080 |
Why?
|
Receptors, Estrogen | 2 | 2013 | 2187 | 0.080 |
Why?
|
Nitriles | 1 | 2013 | 956 | 0.080 |
Why?
|
Proto-Oncogene Proteins | 4 | 2001 | 4554 | 0.080 |
Why?
|
Hepatocyte Growth Factor | 1 | 2010 | 270 | 0.080 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 4751 | 0.080 |
Why?
|
Receptor, IGF Type 1 | 1 | 2010 | 390 | 0.080 |
Why?
|
Prognosis | 5 | 2021 | 29063 | 0.080 |
Why?
|
Animals | 15 | 2016 | 168757 | 0.080 |
Why?
|
Antibodies, Monoclonal | 3 | 2017 | 9274 | 0.080 |
Why?
|
Pyridines | 3 | 2019 | 2825 | 0.080 |
Why?
|
Gene Expression | 4 | 2014 | 7799 | 0.080 |
Why?
|
Endometrial Neoplasms | 1 | 2017 | 1353 | 0.080 |
Why?
|
Cancer Vaccines | 1 | 2015 | 1023 | 0.070 |
Why?
|
Phosphatidylinositol 3-Kinases | 3 | 2013 | 2938 | 0.070 |
Why?
|
Cell Survival | 2 | 2016 | 5882 | 0.070 |
Why?
|
Medical Oncology | 1 | 2018 | 2265 | 0.070 |
Why?
|
Chromatin | 1 | 2018 | 2934 | 0.070 |
Why?
|
Gene Expression Profiling | 2 | 2019 | 9438 | 0.070 |
Why?
|
Sulfonamides | 2 | 2019 | 1938 | 0.070 |
Why?
|
MAP Kinase Signaling System | 1 | 2013 | 1526 | 0.070 |
Why?
|
Vascular Neoplasms | 1 | 2007 | 175 | 0.070 |
Why?
|
Protein Processing, Post-Translational | 1 | 2013 | 1990 | 0.060 |
Why?
|
RNA, Small Interfering | 1 | 2014 | 3505 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 5 | 2001 | 1434 | 0.060 |
Why?
|
Mice | 8 | 2015 | 81183 | 0.060 |
Why?
|
Vena Cava, Inferior | 1 | 2007 | 440 | 0.060 |
Why?
|
Attitude of Health Personnel | 1 | 2018 | 3843 | 0.060 |
Why?
|
Cycloheximide | 2 | 1994 | 347 | 0.060 |
Why?
|
Mutation, Missense | 1 | 2013 | 2564 | 0.060 |
Why?
|
Genetic Association Studies | 1 | 2013 | 2703 | 0.060 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2010 | 2649 | 0.060 |
Why?
|
Body Weight | 1 | 2014 | 4669 | 0.060 |
Why?
|
Multiprotein Complexes | 1 | 2010 | 1119 | 0.060 |
Why?
|
Cells, Cultured | 4 | 2014 | 19229 | 0.050 |
Why?
|
Proteins | 3 | 2010 | 6103 | 0.050 |
Why?
|
Cell Movement | 1 | 2014 | 5217 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 3 | 2019 | 6538 | 0.050 |
Why?
|
Stomach Neoplasms | 1 | 2011 | 1333 | 0.050 |
Why?
|
Multiple Myeloma | 1 | 2019 | 5181 | 0.050 |
Why?
|
Nucleic Acid Hybridization | 2 | 1993 | 1375 | 0.050 |
Why?
|
Follow-Up Studies | 2 | 2021 | 39050 | 0.050 |
Why?
|
DNA Mutational Analysis | 3 | 2016 | 4186 | 0.050 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2013 | 2245 | 0.050 |
Why?
|
Genes, p53 | 2 | 2011 | 755 | 0.050 |
Why?
|
Genetic Testing | 1 | 2012 | 3444 | 0.040 |
Why?
|
Diagnostic Imaging | 1 | 2014 | 3507 | 0.040 |
Why?
|
Leukopenia | 1 | 2019 | 212 | 0.040 |
Why?
|
Tumor Suppressor Proteins | 1 | 2010 | 2849 | 0.040 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 2 | 2012 | 379 | 0.040 |
Why?
|
Colorectal Neoplasms | 1 | 2019 | 6773 | 0.040 |
Why?
|
Adolescent | 7 | 2019 | 85781 | 0.040 |
Why?
|
Cell Proliferation | 1 | 2014 | 10481 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2001 | 365 | 0.040 |
Why?
|
DNA-Binding Proteins | 2 | 1993 | 9648 | 0.040 |
Why?
|
Indazoles | 1 | 2019 | 289 | 0.040 |
Why?
|
Cell Division | 2 | 1996 | 4568 | 0.040 |
Why?
|
Transfection | 3 | 1996 | 5892 | 0.040 |
Why?
|
Brain Neoplasms | 1 | 2019 | 8863 | 0.040 |
Why?
|
Anthracyclines | 1 | 2019 | 288 | 0.040 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2015 | 15519 | 0.040 |
Why?
|
Tumor Burden | 2 | 2015 | 1915 | 0.040 |
Why?
|
Carcinoma, Renal Cell | 1 | 2012 | 3143 | 0.040 |
Why?
|
Anorexia | 1 | 2017 | 161 | 0.030 |
Why?
|
Predictive Value of Tests | 1 | 2012 | 15076 | 0.030 |
Why?
|
Lipopolysaccharides | 1 | 2024 | 2216 | 0.030 |
Why?
|
Membrane Proteins | 1 | 2013 | 7880 | 0.030 |
Why?
|
Fibroblasts | 3 | 2000 | 4161 | 0.030 |
Why?
|
Cell Line, Transformed | 2 | 1996 | 898 | 0.030 |
Why?
|
Double-Blind Method | 2 | 2021 | 12026 | 0.030 |
Why?
|
Signal Transduction | 3 | 2016 | 23403 | 0.030 |
Why?
|
Time Factors | 3 | 2016 | 40075 | 0.030 |
Why?
|
Kidney Neoplasms | 1 | 2012 | 4262 | 0.030 |
Why?
|
Basic-Leucine Zipper Transcription Factors | 2 | 1993 | 154 | 0.030 |
Why?
|
Isoleucine | 1 | 1994 | 112 | 0.030 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2019 | 379 | 0.030 |
Why?
|
Paresthesia | 1 | 2015 | 161 | 0.030 |
Why?
|
Phosphotransferases (Alcohol Group Acceptor) | 1 | 1997 | 437 | 0.030 |
Why?
|
Neutropenia | 1 | 2019 | 895 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-sis | 1 | 2015 | 251 | 0.030 |
Why?
|
Oligodeoxyribonucleotides | 2 | 1993 | 708 | 0.030 |
Why?
|
Nausea | 1 | 2017 | 673 | 0.030 |
Why?
|
RNA Probes | 1 | 1993 | 113 | 0.030 |
Why?
|
Vomiting | 1 | 2017 | 636 | 0.030 |
Why?
|
Taxoids | 1 | 2017 | 666 | 0.030 |
Why?
|
Cell Dedifferentiation | 1 | 2014 | 135 | 0.030 |
Why?
|
RNA, Messenger | 3 | 1993 | 13033 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 3 | 2015 | 20129 | 0.030 |
Why?
|
Gene Knockdown Techniques | 1 | 2018 | 1655 | 0.030 |
Why?
|
G1 Phase | 1 | 1994 | 415 | 0.030 |
Why?
|
Gene Expression Regulation | 3 | 2000 | 12072 | 0.030 |
Why?
|
Retreatment | 1 | 2014 | 610 | 0.030 |
Why?
|
Rats | 5 | 2000 | 24260 | 0.030 |
Why?
|
Embryo, Mammalian | 2 | 1996 | 1701 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2017 | 2274 | 0.030 |
Why?
|
3T3 Cells | 1 | 1993 | 1101 | 0.030 |
Why?
|
Collagen Type I | 1 | 2015 | 592 | 0.030 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2014 | 648 | 0.030 |
Why?
|
Perception | 1 | 2018 | 1198 | 0.030 |
Why?
|
Tumor Microenvironment | 1 | 2024 | 3586 | 0.030 |
Why?
|
Purines | 1 | 2015 | 594 | 0.030 |
Why?
|
Gene Rearrangement | 1 | 2017 | 1179 | 0.030 |
Why?
|
Enhancer Elements, Genetic | 1 | 2018 | 1341 | 0.020 |
Why?
|
Chromosomes, Human, Pair 14 | 1 | 1992 | 299 | 0.020 |
Why?
|
Cyclin-Dependent Kinases | 1 | 1994 | 671 | 0.020 |
Why?
|
Antigens, Neoplasm | 1 | 2019 | 1988 | 0.020 |
Why?
|
Tendons | 1 | 2015 | 548 | 0.020 |
Why?
|
Culture Media | 1 | 1993 | 908 | 0.020 |
Why?
|
Crystallography, X-Ray | 1 | 2015 | 2011 | 0.020 |
Why?
|
Retroviridae | 1 | 1993 | 914 | 0.020 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 1992 | 315 | 0.020 |
Why?
|
Molecular Weight | 1 | 1992 | 2255 | 0.020 |
Why?
|
Fatigue | 1 | 2017 | 1531 | 0.020 |
Why?
|
Genes | 1 | 1993 | 1893 | 0.020 |
Why?
|
Thrombocytopenia | 1 | 2017 | 1179 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2017 | 3616 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2018 | 4204 | 0.020 |
Why?
|
Isoenzymes | 1 | 2013 | 1726 | 0.020 |
Why?
|
Treatment Failure | 1 | 2014 | 2618 | 0.020 |
Why?
|
Antigens, CD | 1 | 2019 | 4026 | 0.020 |
Why?
|
Cohort Studies | 3 | 2019 | 40561 | 0.020 |
Why?
|
Ventricular Function, Left | 1 | 2021 | 3670 | 0.020 |
Why?
|
Child | 2 | 2015 | 77709 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 3870 | 0.020 |
Why?
|
Cell Line | 3 | 2000 | 15997 | 0.020 |
Why?
|
Base Sequence | 3 | 1996 | 12797 | 0.020 |
Why?
|
Transcriptional Activation | 1 | 1993 | 1783 | 0.020 |
Why?
|
Drug Discovery | 1 | 2015 | 1058 | 0.020 |
Why?
|
Gene Deletion | 1 | 2015 | 2751 | 0.020 |
Why?
|
Estrogens | 1 | 1993 | 1566 | 0.020 |
Why?
|
Gastrectomy | 1 | 2011 | 663 | 0.020 |
Why?
|
Cloning, Molecular | 1 | 1992 | 4320 | 0.020 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2010 | 652 | 0.020 |
Why?
|
RNA Interference | 1 | 2015 | 2889 | 0.020 |
Why?
|
Protein Biosynthesis | 1 | 1993 | 2126 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2018 | 8428 | 0.020 |
Why?
|
Molecular Sequence Data | 3 | 1996 | 18111 | 0.020 |
Why?
|
DNA, Neoplasm | 1 | 2011 | 1758 | 0.020 |
Why?
|
Physician-Patient Relations | 1 | 2018 | 3229 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 1 | 1993 | 3772 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 1993 | 6386 | 0.020 |
Why?
|
Survival Analysis | 1 | 2017 | 10252 | 0.010 |
Why?
|
Hippocampus | 1 | 1996 | 3675 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 1992 | 6314 | 0.010 |
Why?
|
Research Design | 1 | 2019 | 5987 | 0.010 |
Why?
|
Chromosome Mapping | 1 | 1992 | 4740 | 0.010 |
Why?
|
Alleles | 1 | 1994 | 6933 | 0.010 |
Why?
|
Genetic Vectors | 1 | 1993 | 3420 | 0.010 |
Why?
|
DNA Damage | 1 | 1993 | 2432 | 0.010 |
Why?
|
Incidence | 1 | 2021 | 20947 | 0.010 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2011 | 2016 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2014 | 8642 | 0.010 |
Why?
|
United States | 1 | 2010 | 69872 | 0.010 |
Why?
|
Repressor Proteins | 1 | 1993 | 3023 | 0.010 |
Why?
|
Genes, bcl-2 | 1 | 2001 | 122 | 0.010 |
Why?
|
Contrast Media | 1 | 2014 | 5300 | 0.010 |
Why?
|
Age Factors | 1 | 2017 | 18370 | 0.010 |
Why?
|
Antibodies, Neutralizing | 1 | 2010 | 1978 | 0.010 |
Why?
|
Zebrafish | 1 | 2011 | 2994 | 0.010 |
Why?
|
bcl-2-Associated X Protein | 1 | 2001 | 295 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2009 | 5078 | 0.010 |
Why?
|
Lymph Nodes | 1 | 2011 | 3474 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2013 | 12354 | 0.010 |
Why?
|
Structure-Activity Relationship | 2 | 1996 | 3129 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 1993 | 7722 | 0.010 |
Why?
|
Melanoma | 1 | 2017 | 5510 | 0.010 |
Why?
|
Drug Delivery Systems | 1 | 2010 | 2219 | 0.010 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 5221 | 0.010 |
Why?
|
DNA | 1 | 1992 | 7301 | 0.010 |
Why?
|
Skin Neoplasms | 1 | 2017 | 5686 | 0.010 |
Why?
|
Oncogene Protein pp60(v-src) | 1 | 1997 | 77 | 0.010 |
Why?
|
Neurons | 1 | 1996 | 9338 | 0.010 |
Why?
|
Amino Acid Chloromethyl Ketones | 1 | 1996 | 68 | 0.010 |
Why?
|
Culture Media, Serum-Free | 1 | 1996 | 158 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 1994 | 21827 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-raf | 1 | 1997 | 203 | 0.010 |
Why?
|
Antigens, Viral, Tumor | 1 | 1996 | 154 | 0.010 |
Why?
|
Genotype | 1 | 2011 | 12951 | 0.010 |
Why?
|
Simian virus 40 | 1 | 1996 | 295 | 0.010 |
Why?
|
Receptors, Growth Factor | 1 | 1997 | 334 | 0.010 |
Why?
|
Caspase 1 | 1 | 1996 | 224 | 0.010 |
Why?
|
bcl-X Protein | 1 | 1997 | 411 | 0.010 |
Why?
|
Androstadienes | 1 | 1997 | 346 | 0.010 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 1997 | 440 | 0.010 |
Why?
|
Cysteine Endopeptidases | 1 | 1996 | 563 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2009 | 6234 | 0.010 |
Why?
|
Protease Inhibitors | 1 | 1996 | 791 | 0.010 |
Why?
|
DNA Primers | 1 | 1996 | 2892 | 0.010 |
Why?
|
Sequence Deletion | 1 | 1996 | 1526 | 0.010 |
Why?
|
ras Proteins | 1 | 1997 | 1060 | 0.010 |
Why?
|
Macromolecular Substances | 1 | 1993 | 1454 | 0.010 |
Why?
|
Carcinoma | 1 | 2001 | 2375 | 0.010 |
Why?
|
Kinetics | 1 | 1996 | 6473 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 1997 | 3798 | 0.000 |
Why?
|
Amino Acid Sequence | 1 | 1996 | 13815 | 0.000 |
Why?
|
Risk Factors | 1 | 2007 | 72290 | 0.000 |
Why?
|
Prostatic Neoplasms | 1 | 2001 | 11124 | 0.000 |
Why?
|